The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
Open Access
- 8 November 2024
- journal article
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 20 (3) , 69-77
Abstract
Background. Endometrial cancer (EC) treatment outcomes need to be improved. Immunotargeted therapy lead to long-term and delayed effects compared to chemotherapy. Estimation of long-term efficacy and quality of life are crucial when we are talking about efficacy in whole.Aim. To evaluate the long-term clinical efficacy of lenvatinib plus pembrolizumab therapy in patients with EC.Materials and methods. The study included 43 patients with stages I-IV EC with mismatch repair-proficient tumors and treatment duration of more than 9 months. We evaluated median progression-free survival, objective response, duration of treatment depending on the line of therapy, prevalence and type of adverse events, and correction regimens. Results. Lenvatinib plus pembrolizumab treatment was safe and efficacious in recurrent EC. Median of progression-free survival (patients with response or stabilization more than 9 months) is 10.2 months (95 % confidence interval 9.1-13.0), median of follow up is 9.7 (1.4-33.8) months. There were no complete responses, partial response was in 12 (28 %) patients, disease stabilization was in 31 (72 %) patients. Regarding safety, the overall rate of any-grade adverse events was 56.3 %. The most common treatment-related adverse events were fatigue (32.6 %), hypertension (23.3 %), and hypothyroidism (18.6 %). Dose reduction was performed in 22 (51.2 %) patients.Conclusion. The combination of lenvatinib plus pembrolizumab has long-term efficacy and manageable profile of safety. The presence of a significant pool of patients with durable response allows improving the survival rate of such patients in Russia.Keywords
This publication has 10 references indexed in Scilit:
- Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerNew England Journal of Medicine, 2023
- Endometrial cancer: molecular classification and future treatmentsBMJ Medicine, 2022
- Lenvatinib plus Pembrolizumab for Advanced Endometrial CancerNew England Journal of Medicine, 2022
- Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancerGynecologic Oncology, 2021
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial CancerJournal of Clinical Oncology, 2020
- Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 studyAnnals of Oncology, 2018
- New therapies for advanced, recurrent, and metastatic endometrial cancersGynecologic Oncology Research and Practice, 2017
- Tumor grade and chemotherapy response in endometrioid endometrial cancerGynecologic Oncology Reports, 2016
- Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsThe Oncologist, 2016
- Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancerGynecologic Oncology, 2015